K
Karineh Petrossian
Researcher at City of Hope National Medical Center
Publications - 8
Citations - 209
Karineh Petrossian is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Antiestrogen & Aromatase. The author has an hindex of 7, co-authored 8 publications receiving 167 citations. Previous affiliations of Karineh Petrossian include California State University, Northridge & Beckman Research Institute.
Papers
More filters
Journal ArticleDOI
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
TL;DR: Both ER and aromatase are important in ER-dependent breast cancer and the development of endocrine resistance and are reported to be modulated by phosphorylation.
Journal ArticleDOI
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)
Makoto Kubo,Noriko Kanaya,Karineh Petrossian,Jingjing Ye,Charles Warden,Zheng Liu,Reiki Nishimura,Tomofumi Osako,Masayuki Okido,Kazuo Shimada,Masato Takahashi,Peiguo Chu,Yate Ching Yuan,Shiuan Chen +13 more
TL;DR: The findings strongly support further investigation of LBH589 as a novel therapeutic strategy for patients with AI-resistant breast cancer, in part by suppressing the NF-κB1 pathway.
Journal ArticleDOI
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
TL;DR: This review article provides general understanding of molecular basis of endocrine resistance of breast cancer and to offer comprehensive review on current treatment options and potential new treatment strategies for endocrine resistant breast cancers.
Journal ArticleDOI
Lectin binding and effects in culture on human cancer and non-cancer cell lines: Examination of issues of interest in drug design strategies
TL;DR: In this paper, two human cell lines, CCL-220/Colo320DM (human colon cancer cells, tumorigenic in nude mice) and CRL-1459/CCD-18Co (nonmalignant human colon cells) were tested for their ability to bind to agarose microbeads derivatized with two lectins, peanut agglutinin (Arachis hypogaea agglutsinin, PNA) and Dolichos biflorus aggluttinin(DBA), and the
Journal ArticleDOI
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
Karineh Petrossian,Duc Nguyen,Chiao Lo,Noriko Kanaya,George Somlo,Yvonne Xiaoyong Cui,Chiun-Sheng Huang,Shiuan Chen +7 more
TL;DR: Targeting dual mTORC1/2 is a possible option for patients who have recurrent disease from previous everolimus treatment, and RPPA results from RAD-R indicated changes to significant regulatory pathways and upregulation of p-AKT expression level associating withEverolimus resistance.